<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Personalized cancer chemotherapy : an effective way of enhancing outcomes in clinics</title>
  </titleInfo>
  <name type="personal">
    <namePart>Lu, Da-Yong</namePart>
    <namePart type="date">1962-</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <typeOfResource>text</typeOfResource>
  <genre authority="marc">bibliography</genre>
  <genre authority="">Electronic books.</genre>
  <genre authority="lcgft">Electronic books.</genre>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">enk</placeTerm>
    </place>
    <dateIssued encoding="marc">2015</dateIssued>
    <copyrightDate encoding="marc">2015</copyrightDate>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <form authority="gmd">electronic resource</form>
    <extent>1 online resource (85 pages) : illustrations (some color).</extent>
  </physicalDescription>
  <abstract>Individualized cancer chemotherapy (ICC) has been designed to meet the requirement of selecting anticancer drugs in clinics and attracting increasing attentions in medical circle and will show more beneficial outcome in the future if we stick on these researches. Personalized Cancer Chemotherapy addresses and reviews this issue by discussing many existing specific strategies of ICC, including drug sensitivity testing, cancer biomarker detections, cancer biomarker-oriented therapy, anticancer drug pharmacogenetics, cancer metastasis therapy, anticancer drug combinations, assistant therapy, mathematics, and computational analysis of cancer malignancy and drug responses, cost effective and finally studies of relationship between different ICC strategies. The relationship between drug response and these techniques or methods is in-depth analyzed, discussed and highlight. Many longstanding key debates and future trends are also intensively discussed, highlighted and debuted with new twists.</abstract>
  <tableOfContents>Introduction -- Drug sensitivity testing -- Individualized cancer chemotherapy via cancer biomarkers or bioinformatics detection -- Pharmacogenetics -- Individualized antimetastatic therapy [1-2] -- Drug combinations -- Assistant chemotherapy -- Cost-effectiveness considerations -- Discussion -- Conclusion.</tableOfContents>
  <note type="statement of responsibility">Da-Yong Lu.</note>
  <note>Includes bibliographical references.</note>
  <subject authority="lcsh">
    <topic>Chemotherapy</topic>
  </subject>
  <subject authority="lcsh">
    <topic>Cancer</topic>
    <topic>Treatment</topic>
  </subject>
  <subject authority="bisacsh">
    <topic>MEDICAL</topic>
    <topic>Pharmacology</topic>
  </subject>
  <subject authority="fast">
    <topic>Cancer</topic>
    <topic>Treatment</topic>
  </subject>
  <subject authority="fast">
    <topic>Chemotherapy</topic>
  </subject>
  <subject authority="mesh">
    <topic>Neoplasms</topic>
    <topic>drug therapy</topic>
  </subject>
  <subject authority="mesh">
    <topic>Antineoplastic Agents</topic>
  </subject>
  <subject authority="mesh">
    <topic>Drug-Related Side Effects and Adverse Reactions</topic>
  </subject>
  <subject authority="mesh">
    <topic>Pharmacogenetics</topic>
    <topic>methods</topic>
  </subject>
  <subject authority="mesh">
    <topic>Precision Medicine</topic>
    <topic>methods</topic>
  </subject>
  <classification authority="lcc">RM263</classification>
  <classification authority="ddc" edition="23">615.58</classification>
  <classification authority="nlm">QV 267</classification>
  <relatedItem type="otherFormat" displayLabel="Print version:">
    <titleInfo>
      <title>Personalized Cancer Chemotherapy</title>
    </titleInfo>
    <originInfo>
      <publisher>Woodhead Pub Ltd 2014</publisher>
    </originInfo>
    <identifier type="local">(DLC)  2014957608</identifier>
    <identifier type="local">(OCoLC)898160939</identifier>
  </relatedItem>
  <relatedItem type="series">
    <titleInfo>
      <title>Woodhead Publishing series in biomedicine ; no. 720</title>
    </titleInfo>
  </relatedItem>
  <identifier type="isbn">9780081003473</identifier>
  <identifier type="isbn">0081003471</identifier>
  <identifier type="isbn" invalid="yes"/>
  <identifier type="isbn" invalid="yes"/>
  <identifier type="lccn">2014957608</identifier>
  <identifier type="uri">http://www.sciencedirect.com/science/book/9780081003466</identifier>
  <location>
    <url displayLabel="ScienceDirect">http://www.sciencedirect.com/science/book/9780081003466</url>
  </location>
  <recordInfo>
    <recordContentSource authority="marcorg">EBLCP</recordContentSource>
    <recordCreationDate encoding="marc">141220</recordCreationDate>
    <recordChangeDate encoding="iso8601">20190328114810.0</recordChangeDate>
    <recordIdentifier source="OCoLC">ocn898423398</recordIdentifier>
    <languageOfCataloging>
      <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
    </languageOfCataloging>
  </recordInfo>
</mods>
